Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Dec 15, 2023 5:22pm
132 Views
Post# 35787588

RE:RE:RE:RE:Multiple Myeloma In General and NCT03605719 Specifically

RE:RE:RE:RE:Multiple Myeloma In General and NCT03605719 SpecificallyIMO only generally and especially if it is IV administration which onc is then it is trying to target more than just the main tumour. Also pela has shown in previous studies where they were targeting a solid tumour and the liver mets disappeared completely in the patient. It used to be showcased in the investor presentions but that was some time ago although I do still have a lot of the old presentations saved.
As for the melanoma approved virus, as I understand it this is by direct injection with the hope of having some distal or metastatic response.
Also of note is that it has been said if we can control the mets then we can basically keep a patient alive through long term management of the mets or that was kind of the thought at one time.
Thing is each type of cancer is different in regards to the makeup especially with solid tumours but the mets may be more typical and easier to control if we can find the right mechanism to deliver to the mets which is an indication that pela through IV administration could possibly accomplish.
Again the above is a lot IMO.

<< Previous
Bullboard Posts
Next >>